Surveillance of invasive mold infections in lung transplant recipients: Effect of antimycotic prophylaxis with itraconazole and voriconazole;Surveillance invasiver fadenpilzmykosen in lungentransplantierten patienten: Effekt antimykotischer prophylaxe mit itraconazol und voriconazol

Mycoses, Supplement

Volumn 48, Issue 1, 2005, Pages 51-55

  Mattner, Frauke ^a   Chaberny, Iris F ^a   Weissbrodt H ^a   Fischer, S ^a   Gastmeier, P ^a   Haubitz, B ^a   Gottlieb, J ^a   Mattner, L ^b   Strueber, Martin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Aspergillosis; Itraconazole; Lung transplantation; Prophylaxis; Voriconazole; Zygomycosis

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; ITRACONAZOLE; VORICONAZOLE;

ASPERGILLUS; CONFERENCE PAPER; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CHEMOPREVENTION; HUMANS; ITRACONAZOLE; LUNG TRANSPLANTATION; PYRIMIDINES; TRIAZOLES;

EID: 17844396497     PISSN: 09437312     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Lau CL, Patterson GA, Palmer SM. Critical care aspects of lung transplantation. J Intensive Care Med 2004; 19: 83-104.
2. Singh N, Arnow PM, Bonham A et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64: 716-20.
3. Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996; 61: 915-9.
4. Fortun J, Martin-Davila P, Sanchez MA et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003; 22: 408-13.
5. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
6. Paradowski LJ. Saprophytic fungal infections and lung transplantation-revisited. J Heart Lung Transplant 1997; 6: 524-31.
7. Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis 2001; 3: 161-7.
8. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002: 34: 7-14.
9. Guermazi A, Gluckman E, Tabti B, Miaux Y. Invasive central nervous system aspergillosis in bone marrow transplantation recipients: an overview. Eur Radiol 2003; 13: 377-88.
10. Mattner F, Weissbrodt H, Strueber M. Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis 2004; 36: 312-4.
11. Fortun J, Martin-Davila P, Moreno S et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52: 813-9.
12. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-33.
13. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350; 950-2.